Patients must be able to swallow tablets whole
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Ability to swallow tablets
Patients must be able to swallow tablets
Ability to swallow the investigational product tablets.
Participants must be able to swallow ribociclib capsules or tablets
Inability to swallow intact tablets
Inability to swallow intact tablets
Must be able to swallow ribociclib and everolimus capsules/tablets
Must be able to swallow LEE and everolimus capsules/tablets
Patients must have the ability to swallow tablets
Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)
Subjects that cannot swallow tablets.
Able to swallow tablets.
Ability to swallow oral tablets without difficulty
Patients must be able to swallow intact tablets
Patients who are not able to swallow intact tablets are not eligible
Inability to swallow intact tablets
Inability to swallow intact tablets
Inability to swallow intact tablets
Has an inability to swallow tablets or capsules
Able to swallow bicalutamide and ribociclib capsules/tablets.
Be able to swallow tablets.
Are able to swallow capsules and tablets.
Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible
Able to swallow the study drugs whole as tablets
Patients must be able to swallow whole tablets
CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
Inability to swallow tablets or capsules
Patients who cannot swallow whole tablets (i.e. medication tablets)
Willing to take abiraterone acetate on an empty stomach, and should be able to swallow tablets whole, without crushing/chewing tablets; must have the ability to swallow, retain, and absorb oral medication
Part E: Are able to swallow capsules or tablets
Inability to swallow intact tablets or inability to take pembrolizumab or cabozantinib
Ability to swallow epacadostat tablets. In case Incyte at a later time point provides support to administer epacadostat tablets parenterally (via gastrostomy [G]-tube), such administration would also be acceptable as an alternative (once official documentation has been obtained from Incyte)
The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption
Patients who are not able to swallow capsules or tablets
Must be able to swallow ribociclib and tamoxifen capsules/tablets
Patients must be able to swallow tablets whole
Patients must be able to swallow capsules/tablets
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
For subjects to be enrolled in Cohort : Able to swallow and retain orally administered tablets
Patients must have the ability to swallow tablets
Are able to swallow capsules and tablets.
Any condition causing an inability to swallow tablets.
Must be able to swallow ribociclib / placebo capsules/tablets
Inability to swallow tablets
Inability to swallow tablets or capsules
Able to swallow tablets
Inability to swallow tablets
Patients must be willing and able to swallow oral tablets
Patients must have the ability to swallow tablets
Inability to swallow tablets or use of a feeding tube
Are able to swallow tablets
Patients must be able to swallow tablets
Patients with an inability to swallow tablets or capsules
Are able to swallow capsules or tablets
Ability to swallow tablets without difficulty;
Patients must be able to swallow tablets
Able to swallow tablets
Ability to swallow intact palbociclib capsules and bicalutamide tablets
Patients must be able to swallow whole tablets (for MK-); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients who are not able to swallow capsules or tablets
Ability to swallow tablets.
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients must be able to swallow tablets whole, without crushing
Patients must be able to swallow whole tablets; tablets must not be crushed or chewed
Patients must be able to swallow whole tablets and capsules
Inability to swallow tablets for everolimus arm
Patient must be able to swallow whole tablets
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Must be able to swallow tablets and capsules
Inability to swallow tablets
Inability to swallow tablets
Ability to swallow oral tablets
Ability to swallow and tolerate oral tablets
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
Subjects must be able to swallow capsules/tablets
